ImmuCell Corp Files 8-K Report

TL;DR

ImmuCell filed an 8-K, mostly procedural stuff, check for details.

AI Summary

On June 5, 2024, ImmuCell Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events detailed in the provided text. The report confirms ImmuCell Corporation's identity, incorporation in Delaware, and principal executive offices in Portland, Maine.

Why It Matters

This filing serves as an official record with the SEC, indicating that ImmuCell Corporation is fulfilling its reporting obligations. Investors and analysts will review this for any material updates.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently increases risk.

Key Numbers

• 001-12934 — SEC File Number (ImmuCell Corporation's SEC file number)
• 01-0382980 — IRS Employer Identification No. (ImmuCell Corporation's IRS EIN)

Key Players & Entities

• ImmuCell Corporation (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Portland, Maine (location) — Address of principal executive offices
• June 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The Nasdaq

Filing Documents

• ea0207422-8k_immucell.htm (8-K) — 26KB
• ea020742201ex99-1_immucell.htm (EX-99.1) — 14KB
• 0001213900-24-050197.txt ( ) — 212KB
• iccc-20240605.xsd (EX-101.SCH) — 3KB
• iccc-20240605_lab.xml (EX-101.LAB) — 33KB
• iccc-20240605_pre.xml (EX-101.PRE) — 22KB
• ea0207422-8k_immucell_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On June 5, 2024 ImmuCell Corporation (the "Company") issued a press release announcing an update on the regulatory status of its product development initiative with respect to Re-Tain . The information in Item 8.01 and Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated June 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: June 6, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated June 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR